Myocardial bradykinin production during coronary balloon angioplasty in humans

European Journal of Clinical Investigation

Volumn 29, Issue 7, 1999, Pages 571-576

  MacCarthy, P ^a   Prendergast, B ^a   Williams, J ^a   Penny, W ^a   Shah, A ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angioplasty; Bradykinin; Human; Ischaemia; Myocardium; Preconditoning

Indexed keywords

BRADYKININ;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY SINUS; FEMALE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AORTA, THORACIC; BRADYKININ; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; TIME FACTORS;

EID: 0033029778     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00493.x     Document Type: Article

References (30)

1. 1 Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins, kallikreins, kininogens and kininases. Pharmacol Rev, 1992; 44: 1-80.
2. 2 Linz W, Wiemer G, Gohlke P, Unger T, Scholkens A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev, 1995; 47: 25-49.
3. 3 Hartman JC, Theron MW, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol, 1993; 21: 996-1003.
4. 4 Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br J Pharmacol, 1991; 104: 294-5.
5. 5 de Tobe TJM, Langen CDJ, Tio RA, Bel KJ, Mook PH, Wesseling H. Effects of bradykinin on inducible sustained ventricular tachycardia two weeks after myocardial infarction in the pig. J Cardiovasc Pharmacol, 1991; 17: 701-6.
6. 6 Starkopf J, Bugge E, Ytrehus K. Preischaemic bradykinin and ischaemic preconditioning in functional recovery of the globally ischaemic rat heart. Cardiovasc Res, 1997; 33: 63-70.
7. 7 Zeitlin IJ, Fagbemi SO, Parratt JR. Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity. Cardiovasc Res, 1989; 23: 91-7.
8. 8 Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res, 1993; 27: 334-40.
9. 9 Vegh A, GyPapp J, Parratt JR. Attenuation of the antiarhythmic effects of ischaemic preconditioning by blockade of bradykinin B2 receptors. Br J Pharmacol, 1994; 113: 1167-72.
10. 10 Wall TM, Sheely R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther, 1994; 270: 681-9.
11. 11 Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res, 1995; 77: 611-21.
12. 12 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation, 1986; 74: 1124-36.
13. 13 Hashimoto K, Hirose M, Furukawa S, Hayakawa H, Kimura E. Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Japan Heart J, 1977; 18: 679-89.
14. 14 Baumgarten CR, Linz W, Kunkel G, Scholkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol, 1993; 108: 293-5.
15. 15 Matsuki T, Shoji T, Yoshida S, et al. Sympathetically induced myocardial ischaemia causes the heart to release plasma kinin. Cardiovasc Res, 1987; 21; 428-32.
16. 16 Eltchaninoff H, Cribier A, Tron C, et al. Adaptation to myocardial ischaemia during coronary angioplasty demonstrated by clinical, electrocardiographic, echocardiographic, and metabolic parameters. Am Heart J, 1997; 133: 490-6.
17. 17 Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischaemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic and metabolic features. Circulation, 1990; 82: 2044-51.
18. 18 Eldar M, Hollander G, Schulhoff N et al. Bradykinin level in the great cardiac vein during balloon angioplasty of the left anterior descending coronary. Am J Cardiol, 1992; 70: 1621-3.
19. 19 Parratt JR, Vegh A, Zeitlin J et al. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol, 1997; 80 (3A): 124A-131A.
20. 20 Armitage P, Berry G. Statistical methods in medical research, 3rd edn. Blackwell Scientific Publications Oxford, UK; 1994: p.207-15.
21. 21 Bonner G, Iwersen D, Shimamoto K. The analytical value for kinin concentration in blood depends on the antiserum used in the bradykinin radioimmunoassay. J Clin Chem Clin Biochem, 1987; 25: 39-43.
22. 22 Parratt JR. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res, 1993; 27: 693-702.
23. 23 Kolber-Postepska B. Changes in the plasma kinin system in patients with myocardial infarction. Cor Vasa, 1975; 17: 169-76.
24. 24 Edery H, Lewis GP. Inhibition of plasma kininase activity at slightly acid pH. Br J Pharmacol, 1962; 19: 299-305.
25. 2 receptor activation in human heart. J Am Coll Cardiol, 1997; 29: 1599-606.
26. 26 Drexler H, Zeiher AM, Wollschlager H, Meinertz T, Just H, Bonzel T. Flow-dependent coronary artery dilatation in humans. Circulation, 1989; 80: 466-74.
27. 27 Ahmad M, Zeitlin IJ, Parratt JR, Valen G, Takeshima S, Vaage J. Changes in bradykinin levels in the blood of patients undergoing cardiopulmonary bypass. J Physiol, 1996; 494: 116-7P.
28. 28 Levinsky NG. The renal kallikrein-kinin system. Circ Res, 1979; 44: 441-51.
29. 29 Kurita A, Takase B, Uehata A, et al. Differences in plasma β endorphin and bradykinin levels between patients with painless or with painful myocardial ischaemia. Am Heart J, 1992; 123: 304-9.
30. 30 Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation, 1995; 92: 3424-30.